We serve Chemical Name:2-fluoro-3-(4-hydroxyphenyl)propanoic acid CAS:53786-98-4 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:2-fluoro-3-(4-hydroxyphenyl)propanoic acid
CAS.NO:53786-98-4
Synonyms:Benzenepropanoic acid,a-fluoro-4-hydroxy;3-(4-Hydroxyphenyl)-2-fluorpropionsaeure;2-Fluoro-3-(p-Hydroxyphenyl)propanoicacid
Molecular Formula:C9H9FO3
Molecular Weight:184.16400
HS Code:2918290000
Physical and Chemical Properties:
Melting point:N/A
Boiling point:358.3ºC at 760 mmHg
Density:1.338g/cm3
Index of Refraction:1.552
PSA:57.53000
Exact Mass:184.05400
LogP:1.35740
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like Benzenepropanoic acid,a-fluoro-4-hydroxy chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,2-Fluoro-3-(p-Hydroxyphenyl)propanoicacid physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,3-(4-Hydroxyphenyl)-2-fluorpropionsaeure Use and application,2-Fluoro-3-(p-Hydroxyphenyl)propanoicacid technical grade,usp/ep/jp grade.
Related News: The travel restrictions will take effect on Tuesday, Prime Minister Chung Sye-kyun said, as the number of people testing positive for the coronavirus in South Korea increased to 15. 2-fluoro-3-(4-hydroxyphenyl)propanoic acid manufacturer Additional results from the trial with data on another goal of extending survival is expected in 2020, AstraZeneca said. 2-fluoro-3-(4-hydroxyphenyl)propanoic acid supplier First of all, as an API manufacturer we think of how to make a chemical compound which becomes an API in the laboratory. 2-fluoro-3-(4-hydroxyphenyl)propanoic acid vendor In addition to APIs, a variety of pharmaceutical excipients are contained in the medicine. 2-fluoro-3-(4-hydroxyphenyl)propanoic acid factory Additional results from the trial with data on another goal of extending survival is expected in 2020, AstraZeneca said.